Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major health concern with no approved pharmacological therapies. Molecules developed to activate the bile acid-receptor TGR5 regulate pathways involved in MALFD pathogenesis, but the therapeutic value of TGR5 activation on the active...
Main Authors: | Justine Gillard, Corinne Picalausa, Christoph Ullmer, Luciano Adorini, Bart Staels, Anne Tailleux, Isabelle A. Leclercq |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/14/13/2707 |
Similar Items
-
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
by: Andrea Boccatonda, et al.
Published: (2023-03-01) -
Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
by: Francesca Fianchi, et al.
Published: (2021-06-01) -
Research Progress of Takeda G Protein-Coupled Receptor 5 in Metabolic Syndrome
by: Xianmei Gou, et al.
Published: (2023-08-01) -
Endoplasmic Reticulum and Mitochondria Contacts Correlate with the Presence and Severity of NASH in Humans
by: Chaonan Jin, et al.
Published: (2022-07-01) -
Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
by: Nicolas Lanthier, et al.
Published: (2022-08-01)